HC Wainwright Reaffirms Buy Rating for Context Therapeutics (NASDAQ:CNTX)

HC Wainwright reissued their buy rating on shares of Context Therapeutics (NASDAQ:CNTX) in a report released on Monday morning, Benzinga reports. The firm currently has a $6.00 target price on the stock.

Context Therapeutics Stock Down 5.8 %

CNTX opened at $1.96 on Monday. Context Therapeutics has a 52-week low of $0.77 and a 52-week high of $2.75. The company has a market cap of $147.00 million, a P/E ratio of -1.47 and a beta of 2.31. The firm’s 50-day moving average price is $2.31 and its 200-day moving average price is $1.86.

Context Therapeutics (NASDAQ:CNTX) last issued its earnings results on Wednesday, August 7th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.04. On average, research analysts anticipate that Context Therapeutics will post -0.31 EPS for the current fiscal year.

Institutional Investors Weigh In On Context Therapeutics

A number of large investors have recently bought and sold shares of CNTX. Great Point Partners LLC purchased a new stake in Context Therapeutics in the second quarter valued at approximately $14,876,000. Blue Owl Capital Holdings LP purchased a new stake in Context Therapeutics in the 2nd quarter worth approximately $10,348,000. Driehaus Capital Management LLC purchased a new stake in Context Therapeutics in the 2nd quarter worth approximately $4,527,000. Nantahala Capital Management LLC purchased a new stake in Context Therapeutics in the 2nd quarter worth approximately $3,881,000. Finally, Affinity Asset Advisors LLC boosted its position in Context Therapeutics by 392.4% in the 2nd quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock worth $3,246,000 after purchasing an additional 1,290,323 shares in the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.